DR Reddys Laboratories LTD (RDY)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $14.15
- As of
Kresmion compiles this page from RDY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
DR REDDYS LABORATORIES LTD (RDY): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-26.
See the full RDY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RDY on one page. Preview it with sample data, then open it live with a free account.
Preview the RDY dossierActive events for RDY
- mediumEarnings above estimates
Q2-2027: Beat consensus by 21.9%, EPS $11.3976 vs $9.3474 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 75% of RDY (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 94% of RDY (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +721% to RDY (2026Q2)
- mediumEarnings below estimates
Q1-2027: Missed consensus by 36.9%, EPS $5.789351999999999 vs $9.1698 estimate
FREE, NO ACCOUNT
Every event on RDY, as it fires
You are seeing 5 of 8 events recorded on RDY since 2026-06-01.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RDY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 256135203 · 2026Q2 | $106.5M | 0.15% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 256135203 · 2026Q2 | $6.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 256135203 · 2026Q2 | $1.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 256135203 · 2026Q2 | $1.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RDY
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
RDY against its peers
RDY's operating margin of 22.1% ranks in the 92nd percentile of 19 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-12-31.
| Metric | RDY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 326B INR | n/a | n/a | 0 |
| Revenue YoY | 16.6% | 2.0% | 81 | 7 |
| Gross margin | 58.5% | 55.4% | 60 | 20 |
| Operating margin | 22.1% | 7.5% | 93 | 19 |
| Net margin | 17.6% | -3.4% | 88 | 20 |
| Return on equity | 17.0% | -3.5% | 92 | 17 |
Peers (21): ELAN, KNSA, INDV, RGC, HLN, HCM, PBH, CURLF, PRGO, TAK, TRLV, ALVO, ETON, GTBIF, CRON, HROW, EVO, AQST, EOLS, KMDA, VREOF. Left out: SGIOF (no annual filing), HYPMY (no annual filing), GALDY (no annual filing), JHPCY (no annual filing). Fiscal periods ending between 2024-12-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RDY: 20-F), reported in INR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RDY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RDY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.